JP2023539493A - Ｂｃｌ－２阻害剤への低下した感度を有する患者の治療方法 - Google Patents

Ｂｃｌ－２阻害剤への低下した感度を有する患者の治療方法 Download PDF

Info

Publication number
JP2023539493A
JP2023539493A JP2023513582A JP2023513582A JP2023539493A JP 2023539493 A JP2023539493 A JP 2023539493A JP 2023513582 A JP2023513582 A JP 2023513582A JP 2023513582 A JP2023513582 A JP 2023513582A JP 2023539493 A JP2023539493 A JP 2023539493A
Authority
JP
Japan
Prior art keywords
antibody
upregulated
binding fragment
bcl
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539493A5 (cg-RX-API-DMAC7.html
Inventor
デ ハード ヨハンス
ハルトバーグ アンナ
ジェイコブス ジュリー
ザブロッキ ピョートル
スミス クレイトン
ジョーダン クレイグ
Original Assignee
アルジェニクス ビーブイ
ザ レゲンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディ コーポレート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルジェニクス ビーブイ, ザ レゲンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディ コーポレート filed Critical アルジェニクス ビーブイ
Publication of JP2023539493A publication Critical patent/JP2023539493A/ja
Publication of JP2023539493A5 publication Critical patent/JP2023539493A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023513582A 2020-08-29 2021-08-27 Ｂｃｌ－２阻害剤への低下した感度を有する患者の治療方法 Pending JP2023539493A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072113P 2020-08-29 2020-08-29
US63/072,113 2020-08-29
PCT/EP2021/073816 WO2022043538A1 (en) 2020-08-29 2021-08-27 Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor

Publications (2)

Publication Number Publication Date
JP2023539493A true JP2023539493A (ja) 2023-09-14
JP2023539493A5 JP2023539493A5 (cg-RX-API-DMAC7.html) 2024-09-03

Family

ID=77821706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513582A Pending JP2023539493A (ja) 2020-08-29 2021-08-27 Ｂｃｌ－２阻害剤への低下した感度を有する患者の治療方法

Country Status (10)

Country Link
US (1) US20240182590A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204098A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023539493A (cg-RX-API-DMAC7.html)
KR (1) KR20230061421A (cg-RX-API-DMAC7.html)
CN (2) CN122351461A (cg-RX-API-DMAC7.html)
AU (1) AU2021334165A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188634A1 (cg-RX-API-DMAC7.html)
IL (1) IL300996A (cg-RX-API-DMAC7.html)
MX (1) MX2023002318A (cg-RX-API-DMAC7.html)
WO (1) WO2022043538A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
JP2025541170A (ja) * 2022-12-08 2025-12-18 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト 急性骨髄性白血病のベネトクラクス／低メチル化剤／抗ｃｄ７０剤による治療に対する耐性又は反応性を特定する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127503A1 (en) * 2018-12-18 2020-06-25 Argenx Bvba Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
US10391168B1 (en) * 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017156398A1 (en) 2016-03-10 2017-09-14 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
CN109563096A (zh) 2016-06-09 2019-04-02 雷迪博士实验室有限公司 固体形式的维奈托克和用于制备维奈托克的方法
EP3481397A1 (en) 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax
CN107648185A (zh) 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
US20190177317A1 (en) 2016-08-12 2019-06-13 Mylan Laboratories Limited Process for the preparation of venetoclax
WO2018069941A2 (en) 2016-10-14 2018-04-19 Mylan Laboratories Limited Polymorphic forms of venetoclax
EP3333167A1 (en) 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
WO2018157803A1 (zh) 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
WO2018167652A1 (en) 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127503A1 (en) * 2018-12-18 2020-06-25 Argenx Bvba Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"MOLM-13", JCRB細胞バンクホームページ, JPN6025036255, ISSN: 0005677987 *
"NOMO-1", JCRB細胞バンクホームページ, JPN6025036257, ISSN: 0005677988 *

Also Published As

Publication number Publication date
CN122351461A (zh) 2026-07-10
AU2021334165A1 (en) 2023-03-02
KR20230061421A (ko) 2023-05-08
MX2023002318A (es) 2023-05-19
IL300996A (en) 2023-04-01
CN116249519A (zh) 2023-06-09
CA3188634A1 (en) 2022-03-03
US20240182590A1 (en) 2024-06-06
WO2022043538A1 (en) 2022-03-03
AU2021334165A8 (en) 2023-03-16
EP4204098A1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
JP7822424B2 (ja) 急性骨髄性白血病治療のための抗－ｃｄ７０抗体ａｒｇｘ－１１０の使用
US20250152707A1 (en) Cd70 combination therapy
JP7503887B2 (ja) がんを監視及び治療するための方法
US20240182590A1 (en) Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
HK40089820A (en) Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
EA050897B1 (ru) Способ лечения пациентов с пониженной чувствительностью к ингибитору bcl-2
CA3117282C (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40097470A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40091007A (zh) 用於治疗急性骨髓性白血病的cd70 和bcl-2 抑制剂的组合疗法
HK40052961B (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40049607A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
EA049354B1 (ru) Cd70 и венетоклакс, ингибитор bcl-2, комбинированная терапия для лечения острого миелоидного лейкоза
EA044996B1 (ru) Применение антитела против cd70, argx–110 для лечения острого миелоидного лейкоза
HK40014553A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250902

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127